Tags : 1L

Roche Reports Results of Tecentriq in P-III IMagyn050 Study for

Shots: The P-III IMagyn050 study involves assessing of Tecentriq + Avastin, paclitaxel, and carboplatin vs PBO + Avastin, paclitaxel and carboplatin in the ratio (1:1) in women with Stage III or IV ovarian cancer who are undergoing neoadjuvant or adjuvant therapy The study did not meet its 1EP i.e. PFS while the safety data were consistent […]Read More

Roche’s Tecentriq Receives the US FDA’s Approval as 1L Monotherapy

Shots: The US FDA has approved Tecentriq (atezolizumab) as a 1L Treatment for adults with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells or PD-L1 stained tumor-infiltrating covering ≥ 10% of the tumor area), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations […]Read More

GSK’s Zejula (niraparib) Receives the US FDA’s Approval as 1L

Shots: The approval is based on P-III PRIMA study assessing Zejula (300/200mg, qd) vs PBO in patients with newly diagnosed advanced ovarian cancer following complete or partial response to platinum-based CT regardless of biomarker status The P-III PRIMA study resulted in a 57% improvement in PFS in HRd population and a 38% reduction in the […]Read More

Cue Biopharma Signs Clinical Trial Collaboration with Merck to Evaluate

Shots: Cue Biopharma will conduct a P-I KEYNOTE-A78 study assessing the combination therapy as 1L treatment for HPV+ advanced head and neck cancer. KEYNOTE-A78 will be conducted in parallel with the ongoing P-I study assessing CUE-101 as monothx. post 1L treatment The ongoing P-I dose-escalation and expansion study assessing CUE-101 as a monothx. in post […]Read More